^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Osteosarcoma
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Acta Biochim Biophys Sin (Shanghai)
    Title:

    Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma

    Published date:
    01/12/2021
    Excerpt:
    ...EGFR overexpression counteracted the growth-inhibiting and pro-apoptotic effects of gemcitabine in OS cells. The present study suggests that EGFR promotes tumor progression and contributes to gemcitabine resistance in OS.
    DOI:
    10.1093/abbs/gmaa177